Founded in 2006, WinHealth Pharma is a Hong Kong-headquartered biopharmaceutical company with a comprehensive, end-to-end value chain. The company focuses on three core areas: proprietary pharmaceutical products, CSO business, and specialty care, with a strong commitment to the development and commercialization of cutting-edge medicines. Guided by a patient-first philosophy, we are dedicated to delivering breakthrough therapies and innovative healthcare solutions to patients with cardio-renal diseases, hematologic cancers, gastrointestinal diseases, respiratory and infectious diseases, rare diseases, and other unmet medical needs. Our commitment is to improve patients’ lives through transformative treatments. With a well-established presence in China, WinHealth Pharma is actively expanding across Asia and other international markets, building a comprehensive healthcare ecosystem, driving innovation, and addressing the evolving treatment needs of patients.
Corporate Overview
Leadership Team
Board of Directors
Management
Scientific Advisory Board
Vision, Mission & Values
PURPOSE
Patient comes first
VISION
To build a leading disease ecosystem in Asia Pacific.
MISSION
Providing novel breakthrough therapies for patients with unmet medical needs.
CORE VALUES
Winhealth adheres to the high standard of the following core values in our daily operations and management.
CORE VALUES
Result-Driven: We are result-oriented with demonstrating the extreme execution.
Audacious Innovation: We aim to work out practical solutions to challenge through continuous innovation, creative thinking cultivation and wise risk management.
Responsibility: We take utmost responsibility with the spirit of ownership for our stakeholders including patients, physicians, partners , employees and shareholders.
Entrepreneurship: We constantly make breakthroughs with pioneering ideas and actions by taking initiatives to challenge the status quo, bring forth the new from the old and embrace the unknown and challenges.
Corporate Social Responsibility
Major Investors
-
LYFE CapitalFounded in 2015, LYFE Capital is a dedicated healthcare fund with $1.1 billion in assets under management. LYFE Capital is actively seeking healthcare companies with exceptional management teams and expansive vision geared towards global markets. LYFE Capital's investments focus spans biopharmaceuticals, medical devices, and diagnostics. -
KAITAI CAPITALKAITAI CAPITAL, founded in 2009, is a professional investment management organization that mainly engaged in venture capital, private equity, and wealth management business. Fields of investment include medicine and biotechnology, digital healthcare, artificial intelligence and digital industry, community innovation and consumption upgrading. Currently, the asset under management of KAITAI CAPITAL has reached CNY50 billion (USD$7.2B).
Selected Partners
